ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors

ALK inhibitor crizotinib has shown potent antitumor activity in children with refractory Anaplastic Large Cell Lymphoma (ALCL) and the opportunity to include ALK inhibitors in first-line therapies is oncoming. However, recent studies suggest that crizotinib-resistance mutations may emerge in ALCL pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lovisa, Federica, Cozza, Giorgio, Cristiani, Andrea, Cuzzolin, Alberto, Albiero, Alessandro, Mussolin, Lara, Pillon, Marta, Moro, Stefano, Basso, Giuseppe, Rosolen, Angelo, Bonvini, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395299/
https://www.ncbi.nlm.nih.gov/pubmed/25874976
http://dx.doi.org/10.1371/journal.pone.0121378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395299/
https://www.ncbi.nlm.nih.gov/pubmed/25874976
http://dx.doi.org/10.1371/journal.pone.0121378

Ejemplares similares